Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention
of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin
increases with the severity of atrial cardiopathy.
ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3
clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy
and a recent stroke of unknown cause. Eleven hundred subjects will be recruited over 2.5
years at up to 200 sites in and out of the NINDS StrokeNet consortium. Subjects will be
followed for a minimum of 1.5 years and a maximum of 7 years for the primary efficacy outcome
of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage
and major hemorrhage other than intracranial hemorrhage.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.